Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review

Published:2021-12-12 Issue: Volume: Page:1-12
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Nargesi Shahin¹,Dolatshahi Zeinab²,Rezapour Aziz¹,Alipour Vahid¹,Souresrafil Aghdas²,Farabi Hiro²,Javadmoosavi Seyed Arash¹,Safakhah Mandana¹,Moradi Najmeh¹^ORCID

Affiliation:

1. Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Science, Tehran, Iran

2. Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran

Funder

University of Medical Sciences

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2022.2011721

Reference26 articles.

1. Boolell V, Alamgeer M, David N, et al. The Evolution of Therapy in Non-Small Cell Lung Cancer. Cancer (Basel). 2015;7(3):1815–1846

2. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients WithEGFR-Mutated Advanced Non–Small Cell Lung Cancer

3. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer

4. Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP